Latest Period
Q1 2026
Security Snapshot
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) Institutional Ownership
CUSIP: 230031106
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
65,558,874
Price
$14.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CGEM on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 65,558,874
- Total 13F value
- $931,031,569
- Portfolio coverage rank
- 0%
- Share change
- +2,246,922
- Value change
- +$33,928,575
- Number of holders
- 172
- Shares outstanding
- 61,676,366
- SEC-reported price per share
- $16.15
- Insider filing price
- $16.15
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 230031106.
- 172 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 153 to 172 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $653,889,874 to $931,031,569.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q1 2026.
Security key
230031106
Latest holder period
Q1 2026
13F holders
172
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
CGEM full holder history
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Cullinan Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 230031106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CGEM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 14% | +100% | $50,697,778 | +$24,599,905 | 8,549,084 | +94% | Lynx1 Capital Management LP | 08 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $87,800,933 | +$3,462,579 | 6,161,469 | +4.1% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| Kynam Capital Management, LP | 5.3% | $37,245,019 | 3,114,132 | Kynam Capital Management, LP | 31 Dec 2025 | |||
| Flynn James E | 5% | $17,357,187 | 2,927,013 | Deerfield Mgmt, L.P. | 30 Sep 2025 | |||
| FRANKLIN RESOURCES INC | 3.8% | $17,836,873 | 2,191,262 | Franklin Resources, Inc. | 30 Sep 2024 | |||
| CITADEL ADVISORS LLC | 3.4% | -34% | $11,794,219 | -$6,049,899 | 1,988,907 | -34% | Kenneth Griffin | 30 Sep 2025 |
As of 31 Mar 2026, 172 institutional investors reported holding 65,558,874 shares of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM). This represents 106% of the company’s total 61,676,366 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
88%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | 8,963,500 | 0% | 20% | $127,371,335 |
| MPM BIOIMPACT LLC | 12% | 7,648,268 | 0% | 8.4% | $108,681,888 |
| BVF INC/IL | 9.3% | 5,750,683 | 0% | 2.6% | $81,717,205 |
| BlackRock, Inc. | 7.2% | 4,449,966 | +1.1% | 0% | $63,234,017 |
| Kynam Capital Management, LP | 5% | 3,114,132 | 0% | 2.8% | $44,251,816 |
| STATE STREET CORP | 4.1% | 2,544,115 | +16% | 0% | $36,151,874 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 2,483,034 | 0% | 0% | $35,283,913 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.3% | 2,029,719 | +4201% | 0% | $28,843,000 |
| Blue Owl Capital Holdings LP | 3.1% | 1,909,764 | -19% | 7.3% | $27,137,746 |
| RTW INVESTMENTS, LP | 2.8% | 1,705,960 | 0% | 0.24% | $24,241,692 |
| Venrock Adviser, LLC | 2.2% | 1,379,965 | 0% | 0.73% | $19,609,303 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,368,268 | +5.1% | 0% | $19,447,325 |
| Siren, L.L.C. | 1.9% | 1,193,410 | 0% | 0.47% | $16,958,356 |
| Nextech Invest, Ltd. | 1.9% | 1,141,145 | 0% | 1.1% | $16,215,670 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.8% | 1,112,803 | -10% | 0.37% | $15,812,931 |
| MARSHALL WACE, LLP | 1.7% | 1,049,581 | +153% | 0.02% | $14,914,546 |
| DIMENSIONAL FUND ADVISORS LP | 1.5% | 906,028 | +6.7% | 0% | $12,870,141 |
| Point72 Asset Management, L.P. | 1.5% | 905,376 | +151% | 0.02% | $12,865,393 |
| Nuveen, LLC | 1.3% | 805,700 | +39% | 0% | $11,448,997 |
| Affinity Asset Advisors, LLC | 1.3% | 781,260 | -60% | 0.65% | $11,101,705 |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 0.97% | 595,489 | 0% | 0.97% | $8,461,899 |
| MORGAN STANLEY | 0.96% | 589,483 | -23% | 0% | $8,376,558 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.9% | 552,553 | 0% | 0% | $7,851,778 |
| Elmind Capital, LP | 0.86% | 530,000 | +71% | 2.1% | $7,531,300 |
| TWO SIGMA INVESTMENTS, LP | 0.85% | 522,047 | +11% | 0.01% | $7,418,288 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
21
Latest
Q1 2026
Rows shown
1-21 of 21
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 65,558,874 | $931,031,569 | +$33,928,575 | $14.21 | 172 |
| 2025 Q4 | 63,192,288 | $653,889,874 | +$34,298,477 | $10.35 | 153 |
| 2025 Q3 | 61,075,479 | $362,176,403 | -$12,503,675 | $5.93 | 142 |
| 2025 Q2 | 62,610,123 | $471,432,056 | -$15,598,491 | $7.53 | 141 |
| 2025 Q1 | 64,669,430 | $489,559,204 | -$25,799,469 | $7.57 | 145 |
| 2024 Q4 | 65,580,571 | $798,774,691 | -$43,310,126 | $12.18 | 144 |
| 2024 Q3 | 65,000,732 | $1,087,002,831 | -$1,185,148 | $16.74 | 136 |
| 2024 Q2 | 62,920,773 | $1,097,340,923 | +$411,767,308 | $17.44 | 134 |
| 2024 Q1 | 39,359,979 | $670,698,022 | +$49,224,262 | $17.04 | 113 |
| 2023 Q4 | 36,858,851 | $375,589,972 | +$26,958,804 | $10.19 | 110 |
| 2023 Q3 | 38,010,712 | $344,003,620 | +$11,040,871 | $9.05 | 104 |
| 2023 Q2 | 36,693,312 | $394,818,289 | +$48,696,476 | $10.76 | 102 |
| 2023 Q1 | 32,209,329 | $329,495,842 | -$56,320,751 | $10.23 | 97 |
| 2022 Q4 | 37,711,425 | $397,852,399 | +$5,318,094 | $10.55 | 94 |
| 2022 Q3 | 37,032,227 | $474,756,845 | -$7,043,826 | $12.82 | 94 |
| 2022 Q2 | 37,570,810 | $481,656,895 | +$20,400,666 | $12.82 | 81 |
| 2022 Q1 | 36,763,865 | $384,914,646 | +$4,824,538 | $10.47 | 77 |
| 2021 Q4 | 36,386,962 | $559,714,828 | +$6,266,769 | $15.43 | 74 |
| 2021 Q3 | 33,862,280 | $762,265,836 | +$33,803,888 | $22.57 | 63 |
| 2021 Q2 | 32,250,659 | $828,539,736 | -$17,650,444 | $25.75 | 70 |
| 2021 Q1 | 31,323,171 | $1,298,948,827 | +$1,298,948,827 | $41.67 | 70 |